David Mery

6PUBLICATIONS
24CO-AUTHORS
Medical infection agents (incl. prions)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersGene and molecular therapyPhycology (incl. marine grasses)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 09, 2025
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma.

Fumou Sun, Yan Cheng, Catherine Ma

|Mar 28, 2024
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation.

Wancheng Guo, Christopher Strouse, David Mery

|Jan 22, 2024
Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma.

Xuehan Mao, Wenqiang Yan, David Mery

|Sep 27, 2023
Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS.

Wancheng Guo, Anne Zhan, David E Mery

|May 14, 2022
Analysis of Plant-Plant Interactions Reveals the Presence of Potent Antileukemic Compounds.

David E Mery, Amanda J Compadre, Paola E Ordóñez

Pageof 1

Frequent Collaborators

3 joint publications

Samer Al Hadidi

3 joint publications

Caroline Schinke

2 joint publications

Clyde Baily

2 joint publications

Timothy Cody Ashby